Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells

Future Oncology

Volumn 2, Issue 6, 2006, Pages 705-716

  Waldman, Scott ^a   Fortina, Paolo ^a,e   Surrey, Saul ^b   Hyslop, Terry ^a   Kricka, Larry J ^c   Graves, David J ^d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Colorectal cancer; Esophageal adenocarcinomas; Gastric adenocarcinomas; Interstitial thermal ablation; Metal nanoshells; Metastatic cancer therapy; Near infrared thermal ablation; Parenchymal metastases; Plasmon resonance; Receptor targeting

Indexed keywords

BEVACIZUMAB; CETUXIMAB; ENDOTOXIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GOLD; GUANYLATE CYCLASE; GUANYLATE CYCLASE C; IRINOTECAN; IRON OXIDE; MESSENGER RNA; MONOCLONAL ANTIBODY; OXALIPLATIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TECHNETIUM 99M;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CATHETER ABLATION; CLINICAL TRIAL; COLORECTAL CANCER; CONJUGATION; DISEASE FREE SURVIVAL; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; ESOPHAGUS CANCER; FIBER OPTICS; HISTOPATHOLOGY; HUMAN; INFRARED RADIATION; INTESTINE METAPLASIA; LASER SURGERY; LIGAND BINDING; LIVER METASTASIS; LOW LEVEL LASER THERAPY; LUNG METASTASIS; LYMPH NODE METASTASIS; MACROMOLECULE; MICROMETASTASIS; NANOPARTICLE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTUM DOT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN TUMOR; STOMACH CANCER; TUMOR NECROSIS; TUMOR XENOGRAFT;

COLORECTAL NEOPLASMS; GOLD; GUANYLATE CYCLASE; HUMANS; HYPERTHERMIA, INDUCED; INFRARED RAYS; METAL NANOPARTICLES; NEOPLASM METASTASIS; RECEPTORS, PEPTIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 33845648378     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.2.6.705     Document Type: Article

References (63)

1. Jemal A, Tiwari RC, Murray T et al: Cancer statistics, 2004. C4 Cancer J. Clin. 54, 8-29 (2004).
2. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N. Engl. J. Med. 352, 476-487 (2005).
3. O'Connell JB, Maggard MA, Ko CY: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl. Cancer Inst. 96, 1420-1425 (2004).
4. Ries LA, Wingo PA, Miller DS et al.: The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 88, 2398-2424 (2000).
5. Carrithers SL, Barber MT, Biswas S et al.: Guanylyl cyclase C is a selective marker for metastatic colorectal rumors in human extraintestinal tissues. Proc. Natl. Acad. Sci. USA 93, 14827-14832 (1996).
6. Carrithers SL, Parkinson SJ, Goldstein S et al.: Escherichia coli heat-stable toxin receptors in human colonic tumors. Gastroenterology 107, 1653-1661 (1994).
7. Carrithers SL, Parkinson SJ, Goldstein SD et al.: Escherichia coli heat-stable enterotoxin receptors. A novel marker for colorectal tumors. Dis. Colon Rectum 39, 171-181 (1996).
8. Frick GS, Pitari GM, Weinberg DS et al.: Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev. Mol. Diagn. 5, 701-713 (2005).
9. Lucas KA, Pitari GM, Kazerounian S et al.: Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev. 52, 375-414 (2000).
10. Wolfe HR, Mendizabal M, Lleong E et al.: In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C - specific ligand. J. Nucl. Med. 43, 392-399 (2002).
11. Urbanski R, Carrithers SL, Waldman SA: Internalization of E. coli ST mediated by guanylyl cyclase C in T84 human colon carcinoma cells. Biochim. Biophys. Acta 1245, 29-36 (1995).
12. Almenoff JS, Williams SI, Scheving LA, Judd AK, Schoolnik GK: Ligand-based histochemical localization and capture of cells expressing heat-stable enterotoxin receptors. Mol. Microbiol. 8, 865-873 (1993).
13. Hirsch LR, Stafford RJ, Bankson JA et al.: Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl. Acad. Sci. USA 100, 13549-13554 (2003).
14. O'Neal DP, Hirsch LR, Halas NJ, Payne JD, West JL: Photo-thermal tumor ablation in mice using near-infrared-absorbing nanoparticles. Cancer Lett. 209, 171-176 (2004).
15. Sershen SR, Westcort SL, Halas NJ, West JL: Temperature-sensitive polymernanoshell composites for photothermally modulated drug delivery. J. Biomed. Mater. Res. 51, 293-298 (2000).
16. West JL, Halas NJ: Engineered nanomaterials for biophotonics applications: improving sensing, imaging, and therapeutics. Ann. Rev. Biomed. Eng. 5, 285-292 (2003).
17. Weissleder R: A clearer vision for in vivo imaging. Nat. Biotechnol. 19, 316-317 (2001).
18. Duncan R: The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2, 347-360 (2003).
19. Hainfeld JF, Slatkin DN, Smilowitz HM: The use of gold nanoparticles to enhance radiotherapy in mice. Phys. Med. Biol. 49, N309-N315 (2004).
20. Schulz S, Hyslop T, Haaf J. et al.: A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. Clin. Cancer Res. 12, 4545-4552 (2006).
21. Witek ME, Nielsen K, Walters R et al.: The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. Clin. Cancer Res. 11, 8549-8556(2005).
22. Pantel K, Core RJ, Fodstad O: Detection and clinical importance of micrometastatic disease. J. Natl. Cancer Inst. 91, 1113-1124 (1999).
23. Rothenberg ML, Oza AM, Bigelow RH et al.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a Phase III trial. J. Clin. Oncol. 21, 2059-2069(2003).
24. Thirion P, Michiels S, Pignon JP et al.: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol. 22, 3766-3775 (2004).
25. Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J. Clin. Oncol. 22, 1209-1214 (2004).
26. Hurwitz H, Fehrenbacher L, Novotny W et al.: Bevacizumab plus irinotecan, fluorouracil, and leacovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
27. Goldberg RM, Sargent DJ, Morton RF et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22, 23-30 (2004).
28. Gill S, Loprinzi CL, Sargent DJ et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J. Clin. Oncol. 22, 1797-1806 (2004).
29. Sargent DJ, Goldberg RM, Jacobson SD et al.: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N. Engl. J. Med. 345, 1091-1097 (2001).
30. Birbe R, Palazzo JP, Walters R et al.: Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. Hum. Pathol. 36, 170-179 (2005).
31. Buc E, Vartanian MD, Darcha C, Dechelotte P, Pezet D: Guanylyl cyclase C as a reliable immunohistochemical marker and its ligand Escherichia coli heat-stable enterotoxi as a potential protein-delivering vehicle for colorectal cancer cells. Eur. J. Cancer 41, 1618-1627 (2005).
32. Cagir B, Gelmann A, Park J et al.: Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. Ann. Intern. Med. 131, 805-812 (1999). recurrence in patients with colorectal cancer.
33. Waldman SA, Cagir B, Rakinic J et al.: Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer. Dis. Colon Rectum 41, 310-315 (1998).
34. Chen WS, Chung MY, Liu JH, Liu JM, Lin JK: Impact of circulating free tumor cells in the peripheral blood of colorectal cancer patients during laparoscopic surgery. World J. Surg. 28, 552-557 (2004).
35. + progenitor cells in peripheral blood. J. Clin. Oncol. 19, 3951-3959 (2001).
36. Tien YW, Jeng YM, Hu RH et al.: Intravasation-related metastatic factors in colorectal cancer. Tumour Biol. 25, 48-55 (2004).
37. Tien YW, Lee PH, Hu RH, Hsu SM, Chang KJ: The role of gelatinase in hepatic metastasis of colorectal cancer. Clin. Cancer Res. 9, 4891-4896 (2003).
38. Tien YW, Lee PH, Wang SM, Hsu SM, Chang KJ: Simultaneous detection of colonic epithelial cells in portal venous and peripheral blood during colorectal cancer surgery. Dis. Colon Rectum 45, 23-29 (2002).
39. Park J, Schulz S, Haaf J, Kairys JC, Waldman SA: Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach. Cancer Epidemiol. Biomarkers Prev. 11, 739-744 (2002).
40. Hakki S, Crane M, Hugues M, O'Hanley P, Waldman SA: Solubilization and characterization of functionally coupled Escherichia coli heat-stable toxin receptors and particulate guanylate cyclase associated with the cytoskeleton compartment of intestinal membranes. Int. J. Biochem. 25, 557-566 (1993).
41. Hugues M, Crane MR, Thomas BR et al.: Affinity purification of functional receptors far Escberichia coli heat-stable enterotoxin from rat intestine. Biochemistry 31, 12-16 (1992).
42. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E: Nanocrystal targeting in vivo. Proc. Natl. Acad. Sci. USA 99, 12617-12621 (2002).
43. Gao X, Cui Y, Levenson RM, Chung LW Nie S: In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 22, 969-976 (2004).
44. Jain RK: Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 26, 71-90 (1997).
45. Matsumura Y, Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392 (1986).
46. Loo C, Lin A, Hirsch L et al.: Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol. Cancer Res. Treat. 3, 33-40 (2004).
47. Ferrari M: Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5, 161-171 (2005).
48. Oyewumi MO, Mumper RJ: Influence of formulation parameters on gadolinium entrapment and minor cell uptake using folate-coated nanoparticles. Int. J. Pharm. 251, 85-97 (2003).
49. Josephson L, Tung CH, Moore A, Weissleder R: High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug. Chem. 10, 186-191 (1999).
50. Mahmood U, Weissleder R: Near-infrared optical imaging of proteases in cancer. Mol. Cancer Ther. 2, 489-496 (2003).
51. Ntziachristos V, Bremer C, Weissleder R: Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur. Radiol. 13, 195-208 (2003).
52. Shah N, Cerussi A, Eker C et al.: Noninvasive functional optical spectroscopy of human breast tissue. Proc. Natl. Acad. Sci. USA 98, 4420-4425 (2001).
53. Rovers JP, Saarnak AE, Molina A et al.: Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model. Br. J. Cancer 81, 600-608 (1999).
54. Rovers JP, Schuitmaker JJ, Vahrmeijer AL, van Dierendonck JH, Terpstra OT: Interstitial photodynamic therapy with the second-generation photosensitizer bacteriochlorin a in a rat model for liver metastases. Br. J. Cancer 77, 2098-2103 (1998).
55. Leyendecker JR, Dodd GD III: Minimally invasive techniques for the treatment of liver tumors. Semin. Liver Dis. 21, 283-291 (2001).
56. Veenendaal LM, de Jager A, Stapper G, Borel Rinkes IH, van Hillegersberg R: Multiple fiber laser-induced thermotherapy for ablation of large intrahepatic tumors. Photomed. Laser Surg. 24, 3-9 (2006).
57. Vogl TJ, Muller PK , Mack MG et al: Liver metastases: interventional therapeutic techniques and results, state of the art. Eur. Radiol. 9, 675-684 (1999).
58. Vogl TJ, Straub R, Eichler K, Sollner O, Mack MG: Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy - local tumor control rate and survival data. Radiology 230, 450-458 (2004).
59. van Duijnhoven FH, Rovers JP, Engelmann K et al.: Photodynamic therapy with 5, 10, 15, 20-terrakis (m-hydroxyphenyl) bacteriochlorin for colorectal liver metastases is safe and feasible: results from a Phase I study. Ann. Surg. Oncol. 12, 808-816 (2005).
60. Chen J, Keltner L, Christophersen J et al.: New technology for deep light distribution in tissue for phototherapy. Cancer J. 8, 154-163 (2002).
61. Beavis AW: Is tomotherapy the future of IMRT? Br. J. Radiol. 77, 285-295 (2004).
62. Welsh JS, Patel RR, Ritter MA et al.: Helical tomotherapy: an innovative technology and approach to radiation therapy. Technol. Cancer Res. Treat. 1, 311-316 (2002).
63. Wieland P, Dobler B, Mai S et al.: IMRT for postoperative treatment of gastric cancer: covering large target volumes in the upper abdomen: a comparison of a step-and-shoot and an arc therapy approach. Int. J. Radiat. Oncol. Biol. Pbys. 59, 1236-1244 (2004).